More Videos
- Cowen's "Elan" For Elan
- UBS And Its Guarded Outlook For Merck's Gardasil
- Readers Get Short With Me--Over Amgen
- Biopharma Analyst Musical Chairs
- Abbott, Boston Scientific Stents & Stuff
- A "Short" Story On Amgen
- Merck Muscles In On Migraines
- Boston Scientific: Hurry To The Pre-4th of July Sale On Stents!?
- Credit Suisse Healthier 15: Investors Get Skinny On Fat Fighters
- FDA Delivers One-Two Punch To Merck & Lilly
- PGA Tour: A World (And Ratings) Without Tiger Woods
- Bowyer: The Coming Obama Recession
- Farrell: Signs the Fed Will Defend Dollar?
- Weakening Steel
- Lightning Round: Energy, Big Media and Farm Equipment
- Financial Collapse: Banks Going Quietly Into the Night?
- Cramer: Fashionably Healthy
- Tuesday's Web Extra
- Fast & Furious: Oil, Nascar, Ruby Tuesday...
- El-Erian: Commodity Surge Infecting Everyone
- LSE Shares Soar 11% on Quarterly Revenue Increase
- ExpressJet Airlines Suspends Commercial Operations
- Banks Boost Markets, Strategists Cautious
- GfK Mulls Cash Bid for TNS After WPP Swoop
- Macau's SJM Delays IPO Debut Amid Legal Challenge
- European Shares Set to Join Global Bounce
- South Korea to Ease FX Borrowing in Fresh Flip-Flop
- Australia Consumer Confidence Hits 16-Year Low
 |
CNBC.com |
] . CEO Fred Hassan was in Miami when doctors dropped the bomb on Vytorin and Zetia at the American College of Cardiology meeting.
And then he and his people shifted into crisis mode which resulted in the mid-week announcement of massive job cuts. I've occasionally mentioned this on the blog before, but because the drug industry is such a huge part of the NJ economy, the Star-Ledger has a handful of reporters covering pharma. But the paper kind of operates in the shadow of The New York Times and The Wall Street Journal. Nonetheless, it often cranks out stuff like this that you might not read anywhere else.
In her daily cholesterol-drug prescriptions note to clients, Catherine Arnold at Credit Suisse says on April 4th that Vytorin and Zetia combined had a 14.7 percent share of the total prescriptions in the segment. That's down from 16.3 percent pre-ACC. She's going to keep a close eye on the scripts for the next two months and says she expects "increased volatility" during that time.
related content |
Deutsche Bank's Barbara Ryan in a research note to clients this morning says there could be an immediate 15 percent drop in Vytorin/Zetia prescriptions from March levels. But she's not certain how much staying power it'll have. She writes: "The recommendation for use (of Vytorin and Zetia) 'as a last resort' seemingly comes with a stamp of consensus medical expert approval, which based upon our observations and conversations is NOT the case." The caps are hers.
 |
CNBC.com |
In the early going this morning, SGP is once again one of the top percentage gainers in the sector. Leading the way, though, is Wyeth [WYE
Loading...
()
] which was featured in a very bullish article in Barron's over the weekend and is the biggest dollar gainer.
From 'Fast Money': |
Elan [ELN
Loading...
()
] is also benefiting from the Barron's write-up because the companies are partners on a promising Alzheimer's drug. Also from Barron's: Pfizer [PFE
Loading...
()
] now ranks 19th on the list of New York Stock Exchange companies with the largest short positions. According to the publication, the number of PFE shares being shorted went up 4.1 million, or 7.2 percent, from March 14th to March 31st.
Questions? Comments?
Del.icio.us
Digg It
Data is a real-time snapshot *Data is delayed at least 15 minutes